Replies to post #1463 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

3Q07 Baraclude sales: $72M, +227% vs 3Q06 and +22% vs 2Q07:

http://biz.yahoo.com/prnews/071025/nyth026.html?.v=101

>>
Sales of BARACLUDE®, an oral antiviral agent for the treatment of chronic hepatitis B, increased to $72 million in the third quarter of 2007 from $22 million in the same period in 2006, due to continued growth across all markets.
<<

It’s now up to a $288M annualized rate and is closing in on Hepsera for the top spot.